Aifa will finance four studies on monoclonal antibodies for over 2 million euros
Covid, Aifa: over 6,000 patients received monoclonals in three months
Monoclonal antibodies, the distribution in Italy entrusted to the Extraordinary Commissioner Arcuri
Speranza has signed a monoclonal decree, yes to the extraordinary distribution
Share
June 29, 2021 The European Commission announced that it has identified five "promising" treatments for covid-19.
These are therapies "that may soon be available" throughout the EU.
Four of these therapies are based on monoclonal antibodies under ongoing review by the European Medicines Agency (EMA). Another is a commercially licensed immunosuppressant whose use could be extended to include Covid treatment.
"We are taking the first step towards a broad portfolio of therapies for the treatment of Covid-19 - comments Stella Kyriakides, EU Commissioner for Health and Food Safety. While vaccination is progressing at an increasing speed, the virus will not disappear and patients will have need for safe and effective treatments to reduce the burden of Covid-19. Our goal is clear, we aim to identify more cutting-edge candidates under development and to authorize at least three new therapies by the end of the year. "
The five products could receive the green light by October. By the same date, the commission will develop a portfolio of at least 10 potential therapies.